Novel approaches for the treatment of psychostimulant and opioid abuse-focus on opioid receptor-based therapies

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: Psychostimulant and opioid addiction are poorly treated. The majority of abstinent users relapse back to drug-taking within a year of abstinence, making 'anti-relapse' therapies the focus of much current research. There are two fundamental challenges to developing novel treatments for drug addiction. First, there are three key stimuli that precipitate relapse back to drug-taking: stress, presentation of drug-conditioned cue, taking a small dose of drug. The most successful novel treatment would be effective against all three stimuli. Second, a large number of drug users are poly-drug users: taking more than one drug of abuse at a time. The ideal anti-Addiction treatment would, therefore, be effective against all classes of drugs of abuse.Areas covered: In this review, the authors discuss the clinical need and animal models used to uncover potential novel treatments. There is a very broad range of potential treatment approaches and targets currently being examined as potential anti-relapse therapies. These broadly fit into two categories: 'memory-based' and 'receptor-based' and the authors discuss the key targets here within.Expert opinion: Opioid receptors and ligands have been widely studied, and research into how different opioid subtypes affect behaviours related to addiction (reward, dysphoria, motivation) suggests that they are tractable targets as anti-relapse treatments. Regarding opioid ligands as novel 'anti-relapse' medication targets, research suggests that a 'non-selective' approach to targeting opioid receptors will be the most effective.

LanguageEnglish
Pages1333-1344
Number of pages12
JournalExpert Opinion on Drug Discovery
Volume9
Issue number11
DOIs
StatusPublished - Nov 2014

Fingerprint

Opioid Receptors
Opioid Analgesics
Recurrence
Street Drugs
Therapeutics
Drug Users
Pharmaceutical Preparations
Research
Ligands
Expert Testimony
Reward
Substance-Related Disorders
Cues
Motivation
Animal Models

Keywords

  • Addiction
  • Buprenorphine
  • Cocaine
  • Heroin
  • Morphine
  • Reinstatement
  • Relapse

ASJC Scopus subject areas

  • Drug Discovery

Cite this

@article{a417351de8fd4eb68993f4e2a9de5743,
title = "Novel approaches for the treatment of psychostimulant and opioid abuse-focus on opioid receptor-based therapies",
abstract = "Introduction: Psychostimulant and opioid addiction are poorly treated. The majority of abstinent users relapse back to drug-taking within a year of abstinence, making 'anti-relapse' therapies the focus of much current research. There are two fundamental challenges to developing novel treatments for drug addiction. First, there are three key stimuli that precipitate relapse back to drug-taking: stress, presentation of drug-conditioned cue, taking a small dose of drug. The most successful novel treatment would be effective against all three stimuli. Second, a large number of drug users are poly-drug users: taking more than one drug of abuse at a time. The ideal anti-Addiction treatment would, therefore, be effective against all classes of drugs of abuse.Areas covered: In this review, the authors discuss the clinical need and animal models used to uncover potential novel treatments. There is a very broad range of potential treatment approaches and targets currently being examined as potential anti-relapse therapies. These broadly fit into two categories: 'memory-based' and 'receptor-based' and the authors discuss the key targets here within.Expert opinion: Opioid receptors and ligands have been widely studied, and research into how different opioid subtypes affect behaviours related to addiction (reward, dysphoria, motivation) suggests that they are tractable targets as anti-relapse treatments. Regarding opioid ligands as novel 'anti-relapse' medication targets, research suggests that a 'non-selective' approach to targeting opioid receptors will be the most effective.",
keywords = "Addiction, Buprenorphine, Cocaine, Heroin, Morphine, Reinstatement, Relapse",
author = "Bailey, {Chris P.} and Husbands, {Stephen M.}",
year = "2014",
month = "11",
doi = "10.1517/17460441.2014.964203",
language = "English",
volume = "9",
pages = "1333--1344",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Novel approaches for the treatment of psychostimulant and opioid abuse-focus on opioid receptor-based therapies

AU - Bailey, Chris P.

AU - Husbands, Stephen M.

PY - 2014/11

Y1 - 2014/11

N2 - Introduction: Psychostimulant and opioid addiction are poorly treated. The majority of abstinent users relapse back to drug-taking within a year of abstinence, making 'anti-relapse' therapies the focus of much current research. There are two fundamental challenges to developing novel treatments for drug addiction. First, there are three key stimuli that precipitate relapse back to drug-taking: stress, presentation of drug-conditioned cue, taking a small dose of drug. The most successful novel treatment would be effective against all three stimuli. Second, a large number of drug users are poly-drug users: taking more than one drug of abuse at a time. The ideal anti-Addiction treatment would, therefore, be effective against all classes of drugs of abuse.Areas covered: In this review, the authors discuss the clinical need and animal models used to uncover potential novel treatments. There is a very broad range of potential treatment approaches and targets currently being examined as potential anti-relapse therapies. These broadly fit into two categories: 'memory-based' and 'receptor-based' and the authors discuss the key targets here within.Expert opinion: Opioid receptors and ligands have been widely studied, and research into how different opioid subtypes affect behaviours related to addiction (reward, dysphoria, motivation) suggests that they are tractable targets as anti-relapse treatments. Regarding opioid ligands as novel 'anti-relapse' medication targets, research suggests that a 'non-selective' approach to targeting opioid receptors will be the most effective.

AB - Introduction: Psychostimulant and opioid addiction are poorly treated. The majority of abstinent users relapse back to drug-taking within a year of abstinence, making 'anti-relapse' therapies the focus of much current research. There are two fundamental challenges to developing novel treatments for drug addiction. First, there are three key stimuli that precipitate relapse back to drug-taking: stress, presentation of drug-conditioned cue, taking a small dose of drug. The most successful novel treatment would be effective against all three stimuli. Second, a large number of drug users are poly-drug users: taking more than one drug of abuse at a time. The ideal anti-Addiction treatment would, therefore, be effective against all classes of drugs of abuse.Areas covered: In this review, the authors discuss the clinical need and animal models used to uncover potential novel treatments. There is a very broad range of potential treatment approaches and targets currently being examined as potential anti-relapse therapies. These broadly fit into two categories: 'memory-based' and 'receptor-based' and the authors discuss the key targets here within.Expert opinion: Opioid receptors and ligands have been widely studied, and research into how different opioid subtypes affect behaviours related to addiction (reward, dysphoria, motivation) suggests that they are tractable targets as anti-relapse treatments. Regarding opioid ligands as novel 'anti-relapse' medication targets, research suggests that a 'non-selective' approach to targeting opioid receptors will be the most effective.

KW - Addiction

KW - Buprenorphine

KW - Cocaine

KW - Heroin

KW - Morphine

KW - Reinstatement

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=84911497154&partnerID=8YFLogxK

UR - http://dx.doi.org/10.1517/17460441.2014.964203

U2 - 10.1517/17460441.2014.964203

DO - 10.1517/17460441.2014.964203

M3 - Article

VL - 9

SP - 1333

EP - 1344

JO - Expert Opinion on Drug Discovery

T2 - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 11

ER -